# Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

> **NCT00387530** · PHASE2 · WITHDRAWN · sponsor: **University of California, San Diego**

## Conditions studied

- Gastric Cancer
- Head and Neck Cancer
- Lymphoma
- Lymphoproliferative Disorder

## Interventions

- **DRUG:** oral sodium phenylbutyrate
- **DRUG:** valganciclovir
- **GENETIC:** polymerase chain reaction
- **GENETIC:** protein expression analysis
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00387530
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-05
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2019-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387530, "Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00387530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*